After primary surgery, 125 patients with epithelial ovarian cancer (International Federation of Gynaecology and Obstetrics [FIGO] 1c + IIb + IIc = 22 patients, FIGO III = 82 patients, FIGO IV = 21 patients) were randomly allocated to receive PC (cisplatin 50 mg/m2 + cyclophosphamide 600 mg/m2 on day 1 every 28 days) (corrected) or PAC (PC + doxorubicin 45 mg/m2). After six cycles, patients clinically disease-free or with resectable residual disease were submitted to second-look surgery. After restaging, patients in surgical complete response (CR) stopped treatment while those responding partially (PR) received six more courses; patients whose disease progressed were excluded from the study. Among patients with measurable disease, the following clinical response rates were observed: PC = 20\% CR, 34.3\% PR, 14.3\% stable disease, and 31.4\% progression; PAC = 40.6\% CR, 15.6\% PR, 12.5\% stable disease, and 31.3\% progression. In the 75 patients submitted to second look, the results have been the following: PC = 39.5\% CR, 36.8\% PR, 7.9\% stable disease, and 15.8\% progression; PAC = 62.2\% CR, 18.9\% PR, 10.8\% stable disease, and 8.1\% progression. The difference in surgical complete response in favor of the PAC regimen is significant (P less than .05). Median survival and progression-free survival were 800 and 400 days, respectively, for PAC arm; median survival and progression-free survival were 680 and 380 days, respectively, for PC. These differences are not significant. Probability of survival was affected by FIGO stage, amount of residual disease, histology, performance status, and response at second look, while no influence was observed according to grade of tumor differentiation and age. Our results demonstrate the usefulness of doxorubicin in terms of surgical CR.

A randomized trial comparing cisplatin plus cyclophosphamide versus cisplatin, doxorubicin, and cyclophosphamide in advanced ovarian cancer / CONTE, Pierfranco; M., Bruzzone; S., Chiara; M. R., Sertoli; M. G., Daga; A., Rubagotti; A., Conio; M., Ruvolo; R., Rosso; L., Santi. - In: JOURNAL OF CLINICAL ONCOLOGY. - ISSN 0732-183X. - STAMPA. - 4:(1986), pp. 965-971.

A randomized trial comparing cisplatin plus cyclophosphamide versus cisplatin, doxorubicin, and cyclophosphamide in advanced ovarian cancer.

CONTE, Pierfranco;
1986

Abstract

After primary surgery, 125 patients with epithelial ovarian cancer (International Federation of Gynaecology and Obstetrics [FIGO] 1c + IIb + IIc = 22 patients, FIGO III = 82 patients, FIGO IV = 21 patients) were randomly allocated to receive PC (cisplatin 50 mg/m2 + cyclophosphamide 600 mg/m2 on day 1 every 28 days) (corrected) or PAC (PC + doxorubicin 45 mg/m2). After six cycles, patients clinically disease-free or with resectable residual disease were submitted to second-look surgery. After restaging, patients in surgical complete response (CR) stopped treatment while those responding partially (PR) received six more courses; patients whose disease progressed were excluded from the study. Among patients with measurable disease, the following clinical response rates were observed: PC = 20\% CR, 34.3\% PR, 14.3\% stable disease, and 31.4\% progression; PAC = 40.6\% CR, 15.6\% PR, 12.5\% stable disease, and 31.3\% progression. In the 75 patients submitted to second look, the results have been the following: PC = 39.5\% CR, 36.8\% PR, 7.9\% stable disease, and 15.8\% progression; PAC = 62.2\% CR, 18.9\% PR, 10.8\% stable disease, and 8.1\% progression. The difference in surgical complete response in favor of the PAC regimen is significant (P less than .05). Median survival and progression-free survival were 800 and 400 days, respectively, for PAC arm; median survival and progression-free survival were 680 and 380 days, respectively, for PC. These differences are not significant. Probability of survival was affected by FIGO stage, amount of residual disease, histology, performance status, and response at second look, while no influence was observed according to grade of tumor differentiation and age. Our results demonstrate the usefulness of doxorubicin in terms of surgical CR.
4
965
971
A randomized trial comparing cisplatin plus cyclophosphamide versus cisplatin, doxorubicin, and cyclophosphamide in advanced ovarian cancer / CONTE, Pierfranco; M., Bruzzone; S., Chiara; M. R., Sertoli; M. G., Daga; A., Rubagotti; A., Conio; M., Ruvolo; R., Rosso; L., Santi. - In: JOURNAL OF CLINICAL ONCOLOGY. - ISSN 0732-183X. - STAMPA. - 4:(1986), pp. 965-971.
Conte, Pierfranco; M., Bruzzone; S., Chiara; M. R., Sertoli; M. G., Daga; A., Rubagotti; A., Conio; M., Ruvolo; R., Rosso; L., Santi
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/738294
Citazioni
  • ???jsp.display-item.citation.pmc??? 8
  • Scopus 152
  • ???jsp.display-item.citation.isi??? 171
social impact